Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNDX5613 monotherapy in progressive acute myeloid leukemia within the AMLM26 INTERCEPT platform
ACTRN12622000582752Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: MRD clearance rate. Started Mar 2023; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12622000582752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000582752.